Here's Some Good News for Novavax That Investors Are Overlooking

Nothing seems to be going right for Novavax (NASDAQ: NVAX) these days. The European Commission granted authorization to Novavax's Nuvaxovid COVID vaccine in December. On Jan. 14, HAS approved Nuvaxovid, making it the fifth COVID-19 vaccine approved in the country.